Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group
Background: To evaluate patient and tumour characteristics, treatment, and their impact on survival in patients with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma. Precedure: Eighty-three consecutive patients who presented with multi-systemic metastases at initial diagnos...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/2/275 |
| _version_ | 1797344489178660864 |
|---|---|
| author | Vanessa L. Mettmann Claudia Blattmann Godehard Friedel Semi Harrabi Thekla von Kalle Leo Kager Matthias Kevric Thomas Kühne Michaela Nathrath Benjamin Sorg Mathias Werner Stefan S. Bielack Stefanie Hecker-Nolting |
| author_facet | Vanessa L. Mettmann Claudia Blattmann Godehard Friedel Semi Harrabi Thekla von Kalle Leo Kager Matthias Kevric Thomas Kühne Michaela Nathrath Benjamin Sorg Mathias Werner Stefan S. Bielack Stefanie Hecker-Nolting |
| author_sort | Vanessa L. Mettmann |
| collection | DOAJ |
| description | Background: To evaluate patient and tumour characteristics, treatment, and their impact on survival in patients with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma. Precedure: Eighty-three consecutive patients who presented with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma were retrospectively reviewed. In cases of curative intent, the Cooperative Osteosarcoma Study Group recommended surgical removal of all detectable metastases in addition to complete resection of the primary tumour and chemotherapy. Results: Eighty-three eligible patients (1.8%) were identified among a total of 4605 individuals with high-grade osteosarcoma. Nine (10.8%) of these achieved complete surgical remission, of whom seven later had recurrences. The median follow-up time was 12 (range, 1–165) months for all patients. Actuarial event-free survival after 1, 2, and 5 years was 9.6 ± 3.2%, 1.4 ± 1.4%, and 1.4 ± 1.4%, and overall survival was 54.0 ± 5.6%, 23.2 ± 4.9%, and 8.7 ± 3.3%. In univariate analyses, elevated alkaline phosphatase before chemotherapy, pleural effusion, distant bones as metastatic sites, and more than one bone metastasis were negative prognostic factors. Among treatment-related factors, the microscopically complete resection of the primary tumour, a good response to first-line chemotherapy, the macroscopically complete resection of all affected tumour sites, and local treatment (surgery ± radiotherapy) of all bone metastases were associated with better outcomes. Tumour progression under first-line treatment significantly correlated with shorter survival times. Conclusion: The outlook for patients with multi-systemic primary metastases from osteosarcoma remains very poor. The utmost importance of surgical resection of all tumour sites was confirmed. For unresectable bone metastases, radiotherapy might be considered. In the patient group studied, standard chemotherapy was often insufficiently effective. In the case of such advanced disease, alternative treatment options are urgently required. |
| first_indexed | 2024-03-08T11:03:21Z |
| format | Article |
| id | doaj.art-7a653d35aed0483aa535841f25b1cace |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T11:03:21Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7a653d35aed0483aa535841f25b1cace2024-01-26T15:34:55ZengMDPI AGCancers2072-66942024-01-0116227510.3390/cancers16020275Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study GroupVanessa L. Mettmann0Claudia Blattmann1Godehard Friedel2Semi Harrabi3Thekla von Kalle4Leo Kager5Matthias Kevric6Thomas Kühne7Michaela Nathrath8Benjamin Sorg9Mathias Werner10Stefan S. Bielack11Stefanie Hecker-Nolting12Cooperative Osteosarcoma Study Group, Paediatrics 5 (Oncology, Haematology, Immunology), Centre for Paediatric, Adolescent and Women’s Medicine, and Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanyCooperative Osteosarcoma Study Group, Paediatrics 5 (Oncology, Haematology, Immunology), Centre for Paediatric, Adolescent and Women’s Medicine, and Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanyDepartment of Thoracic Surgery, Faculty of Science, University of Tubingen, 72076 Tubingen, GermanyHeidelberg Ion Beam Therapy Centre (HIT), Department of Radiation Oncology, University Hospital Heidelberg, 69120 Heidelberg, GermanyRadiologic Institute, Centre for Paediatric, Adolescent and Women’s Medicine, Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanySt. Anna Children’s Hospital, University Hospital for Paediatric and Adolescent Medicine of the Medical University and St. Anna Children’s Cancer Research Institute (CCRI), 1090 Vienna, AustriaCooperative Osteosarcoma Study Group, Paediatrics 5 (Oncology, Haematology, Immunology), Centre for Paediatric, Adolescent and Women’s Medicine, and Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanyUniversity Children’s Hospital Basel, 4031 Basel, SwitzerlandDepartment of Paediatrics and Children’s Cancer Research Centre, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, GermanyCooperative Osteosarcoma Study Group, Paediatrics 5 (Oncology, Haematology, Immunology), Centre for Paediatric, Adolescent and Women’s Medicine, and Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanyOsteopathology Reference Centre, Institute of Pathology, Vivantes Klinikum im Friedrichshein, 10249 Berlin, GermanyCooperative Osteosarcoma Study Group, Paediatrics 5 (Oncology, Haematology, Immunology), Centre for Paediatric, Adolescent and Women’s Medicine, and Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanyCooperative Osteosarcoma Study Group, Paediatrics 5 (Oncology, Haematology, Immunology), Centre for Paediatric, Adolescent and Women’s Medicine, and Stuttgart Cancer Centre, Klinikum Stuttgart–Olgahospital, 70174 Stuttgart, GermanyBackground: To evaluate patient and tumour characteristics, treatment, and their impact on survival in patients with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma. Precedure: Eighty-three consecutive patients who presented with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma were retrospectively reviewed. In cases of curative intent, the Cooperative Osteosarcoma Study Group recommended surgical removal of all detectable metastases in addition to complete resection of the primary tumour and chemotherapy. Results: Eighty-three eligible patients (1.8%) were identified among a total of 4605 individuals with high-grade osteosarcoma. Nine (10.8%) of these achieved complete surgical remission, of whom seven later had recurrences. The median follow-up time was 12 (range, 1–165) months for all patients. Actuarial event-free survival after 1, 2, and 5 years was 9.6 ± 3.2%, 1.4 ± 1.4%, and 1.4 ± 1.4%, and overall survival was 54.0 ± 5.6%, 23.2 ± 4.9%, and 8.7 ± 3.3%. In univariate analyses, elevated alkaline phosphatase before chemotherapy, pleural effusion, distant bones as metastatic sites, and more than one bone metastasis were negative prognostic factors. Among treatment-related factors, the microscopically complete resection of the primary tumour, a good response to first-line chemotherapy, the macroscopically complete resection of all affected tumour sites, and local treatment (surgery ± radiotherapy) of all bone metastases were associated with better outcomes. Tumour progression under first-line treatment significantly correlated with shorter survival times. Conclusion: The outlook for patients with multi-systemic primary metastases from osteosarcoma remains very poor. The utmost importance of surgical resection of all tumour sites was confirmed. For unresectable bone metastases, radiotherapy might be considered. In the patient group studied, standard chemotherapy was often insufficiently effective. In the case of such advanced disease, alternative treatment options are urgently required.https://www.mdpi.com/2072-6694/16/2/275osteosarcomamulti-systemic metastasescombined metastasesprimary metastasessurvival |
| spellingShingle | Vanessa L. Mettmann Claudia Blattmann Godehard Friedel Semi Harrabi Thekla von Kalle Leo Kager Matthias Kevric Thomas Kühne Michaela Nathrath Benjamin Sorg Mathias Werner Stefan S. Bielack Stefanie Hecker-Nolting Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group Cancers osteosarcoma multi-systemic metastases combined metastases primary metastases survival |
| title | Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group |
| title_full | Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group |
| title_fullStr | Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group |
| title_full_unstemmed | Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group |
| title_short | Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group |
| title_sort | primary multi systemic metastases in osteosarcoma presentation treatment and survival of 83 patients of the cooperative osteosarcoma study group |
| topic | osteosarcoma multi-systemic metastases combined metastases primary metastases survival |
| url | https://www.mdpi.com/2072-6694/16/2/275 |
| work_keys_str_mv | AT vanessalmettmann primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT claudiablattmann primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT godehardfriedel primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT semiharrabi primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT theklavonkalle primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT leokager primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT matthiaskevric primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT thomaskuhne primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT michaelanathrath primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT benjaminsorg primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT mathiaswerner primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT stefansbielack primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup AT stefanieheckernolting primarymultisystemicmetastasesinosteosarcomapresentationtreatmentandsurvivalof83patientsofthecooperativeosteosarcomastudygroup |